T4 endonuclease V: review and application to dermatology

Differential Genetic Advantages in Youth and in Aging, or How to Die Healthy

“…cancer screening, antidiabetic therapy, antihypertensive medication) and, with the advent of methodology for assessment of individual repair capacity, it could be expected that the process of making informed decisions so as to decrease the risk of late-age disease would be greatly facilitated in the near future. Moreover, several strategies designed to ensure protection against one of the major proaging and carcinogenic factors -the UV radiation -even after prolonged or repeated encounter with it, have been developed (7,14,21,80). Also, the anticancer and anti-inflammatory properties of some substances commonly found in human food and beverages such as resveratrol and antocyanes in fresh fruit and vegetables, polyphenols in tea and coffee, compounds in herbs and spices such as curcumin, etc.…”

On a Break with the X: The Role of Repair of Double-Stranded DNA Breaks in X-Linked Disease

“…Re(tying) the knot -how the deleterious results of double-strand breaks could be repaired by introducing yet more double-strand breaks Modern research and medicine already possess various tools to assess capacity for DnA repair and, sometimes, to intervene where this is possible (8,16,17,18,20,54,86,99). In vitro assays for the rate of repair of double-strand breaks have been developed in order to be used in testing for cancer susceptibility and radiosensitivity (8,85,88).…”

Recombinant Viral Vectors for Investigating DNA Damage Responses and Gene Therapy of Xeroderma Pigmentosum

“…These studies also showed that even in the higher dose of T4N5 liposomes, only ~50% of the CPD lesions were removed but that was capable of reducing the mutagenesis rate by 99% in transformed fibroblasts and 30% in primary fibroblast cell culture. These numbers are probably not only related to the number of remaining lesions, but also to the smaller size of the repair patch filled by BER compared to that needed in NER (Yarosh, 2002;Cafardi & Elmets, 2008). Finally, after two phase I clinical trials (Yarosh et al, 1996as cited in Cafardi & Elmets, 2008 and three phase II clinical trials (Wolf et al, 2000 andYarosh et al, 1996 as cited in Cafardi & Elmets, 2008), in 2001 the T4N5 liposomes were tested in XP patients.…”

“…Despite the promising results, there are currently no topical DNA repair enzymes approved by the FDA. Clinical trials are still being conducted to analyze the application of T4N5 liposomes in other deficiencies and immunosuppressed patients (Cafardi & Elmets, 2008).…”